8-K: QuidelOrtho Appoints Brian J. Blaser as New President and CEO, Expanding Board

QuidelOrtho Corporation has appointed Brian J. Blaser as its new President and CEO, effective May 6, 2024, and expanded its board to include him as a director.

Summary

• QuidelOrtho Corporation has appointed Brian J. Blaser as President and Chief Executive Officer, effective May 6, 2024.
• The company's board of directors has also appointed Mr. Blaser as a director, effective May 15, 2024, increasing the board size from ten to eleven members.
• The interim Office of the Chief Executive Officer has been dissolved, with Michael S. Iskra and Robert J. Bujarski stepping down from their interim roles but continuing in their respective executive positions.
• Mr. Blaser's compensation includes an annual base salary of $1,000,000, a target bonus of at least 125% of his base salary, and a maximum bonus opportunity of at least 150% of the target.
• He will also receive an annual equity grant valued at $7,000,000, consisting of time-based and performance-based restricted stock units, and a one-time sign-on grant of performance-based RSUs valued at $3,000,000.
• Mr. Blaser will receive a monthly travel and housing allowance through December 2024 and reimbursement for reasonable legal fees related to his employment offer.

Sentiment

Score: 8

Explanation: The appointment of a highly experienced CEO and the clear compensation package are positive indicators. The company is positioning itself for future growth and stability. The sentiment is positive but not overly enthusiastic as there is a transition period.

Positives

• The appointment of Brian J. Blaser brings a seasoned executive with over 25 years of experience in the in-vitro diagnostics industry.
• Mr. Blaser's previous role at Abbott Laboratories included overseeing global diagnostics, which aligns well with QuidelOrtho's business.
• The compensation package includes a significant equity component, aligning Mr. Blaser's interests with those of the shareholders.
• The company has provided a severance and change in control agreement, offering protection to the new CEO.
• The company is providing a monthly travel and housing allowance to support the new CEO's transition.

Negatives

• The company has dissolved the interim Office of the Chief Executive Officer, which may cause some disruption during the transition.
• The company is incurring costs associated with the new CEO's compensation package, including a $10,000 monthly travel and housing allowance through December 2024.

Risks

• The company is undergoing a leadership transition, which could introduce some uncertainty.
• The performance-based equity grants are tied to relative total shareholder return, which may not be fully within the control of the new CEO.
• The company's ability to achieve its growth targets will depend on the new CEO's leadership and execution.

Future Outlook

The company is looking forward to continued growth under the leadership of the new CEO, Brian J. Blaser, and is focused on driving innovation and delivering value to customers, shareholders, and employees.

Management Comments

• Kenneth F. Buechler, Ph.D., Chairman of the Board, stated that Brian brings over 25 years of senior leadership experience in the in-vitro diagnostics industry.
• Brian J. Blaser stated he is honored and excited to join QuidelOrtho as president and CEO during this pivotal point in the Company's journey.
• Brian J. Blaser stated he is eager to collaborate with the QuidelOrtho team to drive innovation and continued growth, while delivering value to customers, shareholders and employees.

Industry Context

The appointment of a seasoned executive like Brian J. Blaser, with extensive experience at Abbott Laboratories, signals QuidelOrtho's commitment to strengthening its position in the competitive in-vitro diagnostics market. This move aligns with the industry trend of companies seeking experienced leaders to drive growth and innovation.

Comparison to Industry Standards

• Brian J. Blaser's compensation package, including a $1,000,000 base salary and significant equity grants, is consistent with executive compensation packages at similar-sized public companies in the medical device and diagnostics industry.
• His previous role as Executive Vice President at Abbott Laboratories, a major player in the diagnostics space, is comparable to the leadership experience found at companies like Roche and Siemens Healthineers.
• The performance-based equity grants tied to relative total shareholder return are a common practice in the industry, aligning executive compensation with shareholder value creation.
• The severance and change in control agreement is also a standard practice for executive-level hires, providing a level of security and protection.

Management Changes

Stakeholder Impact

• Shareholders may view the appointment of a seasoned CEO positively, potentially leading to increased confidence in the company's future performance.
• Employees may experience changes in leadership and direction, which could impact morale and job security.
• Customers may benefit from the new CEO's focus on innovation and customer service.
• Suppliers and creditors may see the leadership change as a sign of stability and growth potential.

Next Steps

• Brian J. Blaser will assume his role as President and CEO on May 6, 2024.
• He will join the Board of Directors on May 15, 2024.
• The company will report its first quarter 2024 financial results on May 8, 2024.

Key Dates

Keywords

QuidelOrtho, Brian J. Blaser, CEO, President, Board of Directors, In-Vitro Diagnostics, Executive Appointment, Compensation, Equity Grant, Leadership Change